Impact of early glomerular filtration rate decline in response to antihypertensive treatment on risk of end-stage kidney disease and cardiovascular outcomes: a systematic review and meta-analysis. Issue 3 (20th March 2022)

• Record Type: Journal Article
• Authors: Gambaro, Alessia; Lombardi, Gianmarco; Ribichini, Flavio L.; Mantovani, Alessandro; Bignamini, Angelo A.; Gambaro, Giovanni
• Is Part Of: Journal of hypertension. Volume 40:Issue 3(2022)
• Page Start: 413
• Page End: 421
• Publication Date: 2022-03-20
• Subjects: antihypertensive agent -- cardiovascular disease -- cardiovascular disease risk factors -- chronic kidney disease -- renal function; Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/HJH.0000000000003066
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Supplemental Digital Content is available in the text Abstract : Blood pressure control, which can induce a slight decrease in the glomerular filtration rate (GFR), plays a nephron- and cardioprotective role. However, the more important early decline in GFR associated with antihypertensive therapy and strict blood pressure targets is still of concern. Since few data are available from trials and observational studies, and the phenomenon is relatively rare, we performed a meta-analysis of available studies. We conclude that major reductions in the glomerular filtration rate occurring soon after starting angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or under intensive blood pressure control predict end-stage kidney disease.